

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

AMERICAN PHARMACISTS ASSN

2. Address:

1100 15th Street, NW Suite 400, WASHINGTON, DC 20005

3. Principal place of business (if different from line 2):

4. Contact Name: ALLISON WILEY

Telephone: 2024297521

E-mail (optional): awiley@aphanet.org

Senate ID #: 3071-12

House ID #:

7. Client Name: ☒ Self

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☒

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Expenses (nearest \$20,000): 367,997.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

☐ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☒ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: AMERICAN PHARMACISTS ASSN Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

HR 3161 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008 HR 2638
Department of Homeland Security Appropriations Act, 2008 HR 1585 National Defense Authorization Act

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BOUGH, MARCIE

Covered Official Position (if applicable): N/A

Name: JAMGOCHIAN, HRANT

Covered Official Position (if applicable): N/A

Name: LUNNER, KRISTINA E.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: AMERICAN PHARMACISTS ASSN Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

HR 2994 National Pain Care Policy Act of 2007 72 FR 61886 - The propoosed draft guidance on Allocating and Targeting Pandemic Influenza Vaccine

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BOUGH, MARCIE

Covered Official Position (if applicable): N/A

Name: JAMGOCHIAN, HRANT

Covered Official Position (if applicable): N/A

Name: LUNNER, KRISTINA E.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: AMERICAN PHARMACISTS ASSN Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Medicare Part D Prescription Drug Benefit Tamper-Resistant Prescription Pad Requirement in Medicaid HR 3090 Patient and Pharmacist Protection Act of 2007 S 1951 Fair Medicaid Drug Payment Act of 2007 HR 3140 Patient Access to Medicaid Generic Prescription Drug Act of 2007 HR 1474 Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007 HR 971 Community Pharmacy Fairness Act HR 3700 Fair Medicaid Drug Payment Act of 2007 HR 3140 Saving Our Community Pharmacies Act of 2007 S 1954 Pharmacy Improvement Act (PhAIM) of 2007 S 1827 Pharmacist Access and Recognition in Medicare (PhARM) of 2007S 1951 Fair Medicaid Drug Payment Act of 2007 S 1474 Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007 S 2161 Community Pharmacy Fairness Act of 2007 S 2031 Patient and Pharmacist Protection Act of 2007S 1951 Fair Medicaid Drug Payment Act of 2007 S 2250 Ambulatory Surgical Center Medicare Payment Modernization Act of 2007 HR 1832 Ambulatory Surgical Center Medicare Payment Modernization Act of 2007 HR 3162 Children's Health and Medicare Protection Act of 2007 Docket No. CMS 2238-FC 72FR39142 - Submitted to the House Small Business Committee "Medicaid Drug Reimbursements: Are CMS Cuts Bad Medicine for Small Businesses and Beneficiaries?"

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BOUGH, MARCIE

Covered Official Position (if applicable): N/A

Name: JAMGOCHIAN, HRANT

Covered Official Position (if applicable): N/A

Name: LUNNER, KRISTINA E.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: AMERICAN PHARMACISTS ASSN Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

Delays in HIPPA required NPI registry Docket No. 2007N-0356 Comments and Statement Submitted on Behind the Counter Availability of Certain Drugs RE: Docket No. CMS-1385-FC. 42 CFR Parts.160. Medicare Program: Amendment if the E-Prescribing Exemption for Computer-Generated Facsimiles Docket No. 2007P-0074 Joint Meeting of the Nonprescription Drugs Advisory Committee and Pediatric Advisory Committee -Cough and Cold Medications use in Children Statements Submitted on the FDA Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Drugs Advisory Committee Over-the-Counter Use of Mevacor (lovastatin) Voluntary Restricted Distribution of 40mg Methadone to Hospitals Statements Submitted to Senate Judiciary Committee on "Electronic Prescribing of Controlled Substances: Addressing Health Care and Law Enforcement Priorities" Docket No. DEA 298 Combat Methamphetamine Epidemic Act 2005 Self-Certification S1276 Methamphetamine Production Prevention Act of 2007 HR 2747 Methamphetamine Production Prevention Act of 2007 HR 3580 Food and Drug Administration Amendments Act of 2007 HR 2900 Food and Drug Administration Amendments Act of 2007 S 1378 Dextromethorphan Distribution Act of 2007 HR 970 Dextromethorphan Distribution Act of 2007 S 1695 Biologics Price Competition and Innovation Act of 2007

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BOUGH, MARCIE
Covered Official Position (if applicable): N/A
Name: JAMGOCHIAN, HRANT
Covered Official Position (if applicable): N/A
Name: LUNNER, KRISTINA E.
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: AMERICAN PHARMACISTS ASSN Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: VET (one per page)

16. Specific lobbying issues:

S 2160 Veterans Pain Care Act of 2007

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BOUGH, MARCIE

Covered Official Position (if applicable): N/A

Name: JAMGOCHIAN, HRANT

Covered Official Position (if applicable): N/A

Name: LUNNER, KRISTINA E.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Apr 18, 2008

Printed Name and Title: ALLISON C. WILEY, POLITICAL AC -

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

Name: POLLEY, CATHERINE

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Apr 18, 2008

Printed Name and Title: -